The Quarterly Drug Pipeline details both agents submitted for FDA review and those in Phase 3 studies with a likelihood to apply to the FDA
3 patients discontinued the treatment before follow up visit 1 due to gastrointestinal side effects
- June 16, 2026 - Now available directly to patients, MyPhenome is the first and only precision obesity test that goes beyond GLP-1 treatment response to help guide treatment decisions across a broad range of obesity therapies and interventions
This Sundays Insider : What happens when your capacity changes faster than your life can keep up
The liposomal delivery system encloses glutathione in lipid vesicles, theoretically enhancing absorption across the intestinal barrier compared to standard oral glutathione, which is poorly absorbed due to enzymatic degradation
Zhu F, Cui Y, Walsh DB, Lavine LC